Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TG 02 - S*Bio/Adastra Pharmaceuticals

Drug Profile

TG 02 - S*Bio/Adastra Pharmaceuticals

Alternative Names: SB 1317; TG02

Latest Information Update: 07 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator S*BIO
  • Developer Adastra Pharmaceuticals; European Organisation for Research and Treatment of Cancer; National Cancer Institute (USA); S*BIO
  • Class Antineoplastics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Anaplastic astrocytoma; Glioblastoma
  • No development reported Cancer; Chronic lymphocytic leukaemia; Leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 03 Jan 2019 Adastra Pharmaceuticals plans to initiate a clinical trial in Glioma (In paediatric patients) in second quarter of 2019
  • 03 Jan 2019 Adastra has patent protection for TG 02
  • 03 Jan 2019 Tragara Pharmaceuticals is now called Adastra Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top